A state jury in Philadelphia has determined that Wyeth’s hormone replacement therapy Prempro caused an Arkansas woman to suffer from breast cancer and ordered the pharmaceutical giant to shell out $1.5 million in compensation.
Not content with a ruling it received in a Michigan court, General Motors Corp. took its case against Royal & Sun Alliance Insurance Group to the Delaware Chancery Court on Friday, accusing the insurance company of trying to avoid paying over $500 million in asbestos claims.
A federal judge has decided to stay all proceedings in a case brought by the State of Colorado against Merck & Co. Inc. that alleges the drug maker fraudulently induced the state to purchase the drug Vioxx.
GlaxoSmithKline PLC launched a preemptive strike ahead of a BBC documentary set to air on Monday that claims the drug maker manipulated trial results of its antidepressant Seroxat and hid a link with teenage suicide.
Boosting controversy over Bayer AG’s Trasylol product, a federal lawsuit has accused the German drug giant of concealing the results of a study that showed the bleeding-reduction drug could cause kidney failure.
The California Supreme Court has ruled that attorneys who file class actions over employment and product liability matters should be allowed better access to the contact information of individuals who may help strengthen their cases.
Plaintiffs alleging that GlaxoSmithKline PLC knew about risks related to adolescents’ use of antidepressant Paxil, but failed to warn doctors and the public, were denied class certification Thursday.
The Ontario Superior Court of Justice has granted class action certification in a $100-million lawsuit that claims the acid reflux drug Prepulsid caused serious cardiac arrhythmias and several deaths.
Bayer Corp. has agreed to pay $8 million to 30 states to settle allegations that the drug company failed to adequately warn consumers about the safety risks associated with recalled cholesterol-lowering drug Baycol.
In a setback for General Motors Corp., a United States Court has dismissed a $900 million claim against insurance company Royal & Sun Alliance Insurance Group Plc brought by the troubled auto company for asbestos-related damages.
One of the three Kentucky lawyers accused of siphoning off money from a $200 million settlement involving Wyeth’s diet drug combination fen-phen has admitted that he and his colleagues destroyed crucial evidence in the case.
Nearly three years after criminal charges were settled in Pfizer Inc.’s illegal marketing of the epilepsy drug Neurontin, a federal judge is considering whether or not to grant class action status in nearly 200 consolidated civil lawsuits.
In another victory for Merck & Co., a woman who blamed her husband’s death on the painkiller Vioxx dropped her lawsuit against the pharmaceutical company on Monday, five weeks before it was scheduled to go to trial.
The third trial over Wyeth Pharmaceuticals’ controversial hormone replacement drug got underway Monday in Arkansas.
Fresh off a $495 million product-liability settlement over Zyprexa, Eli Lilly & Co. is facing more scrutiny, with Illinois and Vermont requesting that the pharmaceutical giant hand over material detailing how it marketed the top-selling schizophrenia drug.
Shell Oil Co. on Monday appealed a federal court's decision to certify a class of property owners who sued the oil giant over a toxic chemical leak that allegedly contaminated Chicago-area wells.
Jurors have failed to reach a unanimous decision in two product liability cases alleging that Merck & Co.’s controversial painkiller Vioxx induced heart attacks.
Consumers have brought a lawsuit against Hewlett-Packard, alleging that the company doesn’t tell its customers that its printer cartridges expire even if they still have ink.
The latest in a growing number of law suits against the makers of an anti-psychotic medication has labeled Astrazenenica contemptible for allegedly misleading the public about life-threatening side-effects of its popular drug.
As an increasing number of U.S. companies look toward the Indian market, a spate of U.S. law firms are shoring up their India-focused practices ahead of an expected wave of cross-border litigation and transactions.